3rd CUHK Sarcoma Masterclass

RT plus immunotherapy holds potential for sarcoma treatment

Natalia Reoutova, 20191119000000

Advances in radiotherapy (RT) and immuno-oncology are poised to benefit sarcoma patients, many of whom do not respond to chemotherapy.

Denosumab of benefit in selected patients with giant cell tumour of bone

Christina Lau, 20191014043654

Denosumab can be of benefit to patients with unresectable giant cell tumour of bone (GCTB) and those who are likely to experience significant morbidity after surgical resection of GCTB.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!

Individualized starting dose of niraparib effective, well tolerated in Chinese patients with recurrent ovarian cancer

Dr Margaret Shi, 09 Oct 2020

Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

Dr Margaret Shi, 14 May 2020

Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.